Postoperative Pain Pipeline Insight 2026 Report Profiles Over 40 Companies and 50 Drugs

GlobeNewswire··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

A new report titled "Postoperative Pain - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com, offering critical insights into over 40 companies and 50 pipeline drugs shaping the postoperative pain landscape. The report features comprehensive profiles of drugs in various phases, from clinical to nonclinical stages, including late-stage candidate PF614 from Ensysce Biosciences, an oxycodone-based medication currently in Phase III trials. Mid-stage products include ATX101 from Allay Therapeutics, a sodium ion channel blocker and biopolymer combination in Phase II for extended relief post knee arthroplasty, and LC-400 from LipoCure, an ultra-long-acting local anesthetic advancing to Phase II. Early-stage highlights feature GB-6002 from G2GBIO, an extended-release ropivacaine injectable in Phase I promising over three days of pain relief with a single dose. The report also covers therapeutic assessment by route of administration, molecule type, and development stage, along with pipeline development activities such as collaborations and licensing.

Impact on assets 1

Health Care▲
Ensysce Biosciences Inc
ENSC
▲ PositiveTechnologyrelevance

PF614, a late-stage Phase III candidate, is highlighted as a key pipeline drug for postoperative pain.

Off-coverage companies 2

Allay Therapeuticsi
Private▲ PositiveTechnologyrelevance

ATX101, a Phase II sodium ion channel blocker and biopolymer combination, is featured as a mid-stage product.

LipoCurei
Private▲ PositiveTechnologyrelevance

LC-400, an ultra-long-acting local anesthetic advancing to Phase II, is mentioned as a mid-stage pipeline drug.